Agneta Månsson-Broberg1, Sergey Rodin2, Ivana Bulatovic3, Cristián Ibarra4, Marie Löfling3, Rami Genead3, Eva Wärdell1, Ulrika Felldin3, Carl Granath3, Evren Alici5, Katarina Le Blanc6, C I Edvard Smith7, Alena Salašová8, Magnus Westgren9, Erik Sundström10, Per Uhlén8, Ernest Arenas8, Christer Sylvén1, Karl Tryggvason11, Matthias Corbascio3, Oscar E Simonson3, Cecilia Österholm12, Karl-Henrik Grinnemo13. 1. Division of Cardiology, Department of Medicine, Karolinska Institutet, 17177 Stockholm, Sweden. 2. Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden. 3. Division of Cardiothoracic Surgery and Anesthesiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden. 4. Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; Cardiovascular & Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca R&D, 43150 Mölndal, Sweden. 5. Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden; Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. 6. Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden; Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden. 7. Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden. 8. Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden. 9. CLINTEC, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden. 10. Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital, 17177 Stockholm, Sweden. 11. Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; Duke-NUS Graduate Medical School, Durham, NC 27710, USA. 12. Division of Cardiothoracic Surgery and Anesthesiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden; Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. 13. Division of Cardiothoracic Surgery and Anesthesiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden; Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. Electronic address: karl-henrik.grinnemo@karolinska.se.
Abstract
The intrinsic regenerative capacity of human fetal cardiac mesenchymal stromal cells (MSCs) has not been fully characterized. Here we demonstrate that we can expand cells with characteristics of cardiovascular progenitor cells from the MSC population of human fetal hearts. Cells cultured on cardiac muscle laminin (LN)-based substrata in combination with stimulation of the canonical Wnt/β-catenin pathway showed increased gene expression of ISL1, OCT4, KDR, and NKX2.5. The majority of cells stained positive for PDGFR-α, ISL1, and NKX2.5, and subpopulations also expressed the progenitor markers TBX18, KDR, c-KIT, and SSEA-1. Upon culture of the cardiac MSCs in differentiation media and on relevant LNs, portions of the cells differentiated into spontaneously beating cardiomyocytes, and endothelial and smooth muscle-like cells. Our protocol for large-scale culture of human fetal cardiac MSCs enables future exploration of the regenerative functions of these cells in the context of myocardial injury in vitro and in vivo.
The intrinsic regenerative capacity of human fetal cardiac mesenchymal stromal cells (MSCs) has not been fully characterized. Here we demonstrate that we can expand cells with characteristics of cardiovascular progenitor cells from the MSC population of human fetal hearts. Cells cultured on cardiac muscle laminin (LN)-based substrata in combination with stimulation of the canonical Wnt/β-catenin pathway showed increased gene expression of ISL1, OCT4, KDR, and NKX2.5. The majority of cells stained positive for PDGFR-α, ISL1, and NKX2.5, and subpopulations also expressed the progenitor markers TBX18, KDR, c-KIT, and SSEA-1. Upon culture of the cardiac MSCs in differentiation media and on relevant LNs, portions of the cells differentiated into spontaneously beating cardiomyocytes, and endothelial and smooth muscle-like cells. Our protocol for large-scale culture of human fetal cardiac MSCs enables future exploration of the regenerative functions of these cells in the context of myocardial injury in vitro and in vivo.
In the developing heart, lineage-tracing experiments in chicks and mice have revealed that the heart mainly develops from mesenchymal progenitors of the first and second heart fields (FHF and SHF, respectively) (Buckingham et al., 2005, Kelly et al., 2014). The cells of the FHF are defined by their co-expression of hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4), TBX5 as well as NKX2.5 (Buckingham et al., 2005, Spater et al., 2014). The mesenchymal progenitors of the SHF originate from the pharyngeal mesoderm and are characterized by their expression of the LIM-homeodomain transcription factor transcription factor Islet-1 (ISL1; Cai et al., 2003, Laugwitz et al., 2005). The progenitors of the SHF mainly contribute to the atria, the outflow tract (OFT), and the right ventricle, whereas the FHF progenitors are involved in the development of the left ventricle (Cai et al., 2003, Moretti et al., 2006, Genead et al., 2010, Laugwitz et al., 2005, Laugwitz et al., 2008, Lam et al., 2009, Yang et al., 2013). Apart from these two major cell sources of the FHF and SHF, the cardiogenic mesoderm also seems to contain a progenitor subpopulation, defined by its expression of TBX18, which contributes to the sinus venosus myocardium (Mommersteeg et al., 2010, Christoffels et al., 2006), while cardiac neural crest cells seem to be involved in valve formation and parasympathetic innervation, as well as the septation of the OFT (Hildreth et al., 2008, Hutson and Kirby, 2007, Waldo et al., 2005).Cardiac colony-forming unit fibroblasts with cardiovascular progenitor properties have also been identified in the fetal and adult hearts of mice and humans (Chong et al., 2011, Chong et al., 2013). These cells demonstrate characteristics of mesenchymal stromal cells (MSCs), express platelet-derived growth factor receptor-alpha (PDGFR-α), and give rise not only to epicardial cells but also to cells that occupy the interstitial, perivascular, and adventitial niches of the heart (Chong et al., 2011, Chong et al., 2013). MSCs in hearts of adult mice have also been shown to express higher levels of specific transcription factors representing the FHF and SHF than bone marrow MSCs (Pelekanos et al., 2012), which might indicate organ-specific characteristics of the MSCs persisting in the myocardium from the fetal stages to adulthood. These findings collectively support the idea that cardiac MSCs may be used as a source of cells with cardiac progenitor characteristics.We have explored the possibility of using the cardiac MSCs of the human fetal heart for expansion of cells with characteristics similar to those of mesenchymal progenitors that contribute to mammalian cardiogenesis. In this study cardiac MSCs were reproducibly recovered from the adherent cell fraction from first trimester human fetal hearts by using defined culturing conditions, including the use of specific laminin (LN) isoforms, in combination with canonical Wnt/β-catenin stimulation. The MSCs expressed ISL1, PDGFR-α, and NKX2.5, where subpopulations also expressed the stemness and potential cardiovascular progenitor markers: kinase insert domain protein receptor (KDR), the human orthologue of FLK1; c-KIT, the receptor for the stem cell factor (Beltrami et al., 2003; (Bearzi et al., 2007, Bearzi et al., 2009), stage-specific embryonic antigen 1 (SSEA-1) (Blin et al., 2010), and TBX18 (Christoffels et al., 2006, Mommersteeg et al., 2010). The fetal cardiac MSCs were multipotent and could be differentiated into elongated, striated, and spontaneously beating cardiomyocytes, endothelial cells, and smooth muscle cell-like cells, also when using defined laminins as substrata. This implies that the unique culturing conditions of human fetal cardiac MSCs using a combination of canonical Wnt/β-catenin stimulation and LN-based matrices facilitate the in vitro propagation of cells with cardiac progenitor characteristics.
Results
Enrichment and Expansion of Fetal Cardiac MSCs
In order to develop a culture protocol for successful propagation of cardiac MSCs, the adherent cell fraction from whole human fetal hearts (gestational weeks 6–10) was prepared as previously described by Laugwitz et al. (2005). This cell fraction contains a mixture of different cell types, including the cardiac MSCs. To activate the transcriptional network known to be involved in embryonic cardiogenesis (Klaus et al., 2007), we focused on the canonical Wnt/β-catenin signaling pathway, which has previously been shown to be effective in expansion of SHF progenitors derived from embryonic stem cells from mice and humans (Qyang et al., 2007, Kwon et al., 2007, Moretti et al., 2006, Bu et al., 2009) (Figure 1A).
Figure 1
Derivation of Multipotent MSCs from Human Fetal Hearts
(A) Schematic representation of the experimental procedure used to generate and expand multipotent cardiac MSCs from the adherent cell fraction of human fetal hearts (gestational weeks 6–10).
(B) The initial adherent MSC fraction was cultured under different conditions: Wnt-medium + Geltrex (green), Wnt-medium + plastic (red), medium without Wnt3a + Geltrex (blue), and medium without Wnt3a + plastic (gray).
(C) mRNA expression levels of cardiogenic genes in response to the different culture conditions depicted in (B). Data are normalized against the cells cultured with Wnt3a + Geltrex and presented as mean ± SD of three independent experiments performed in quadruplicate. See also Figure S1.
(D) Western blot analysis confirmed the activation of the Wnt/β-catenin pathway in the cultured human fetal cardiac MSCs (hfcMSC), demonstrating increased levels of both phosphorylated S1490-Lrp6 and Dvl3 (left panel) as well as active (dephosphorylated) β-catenin (ABC) (right panel) compared with the initial adherent cell fraction. β-Actin was used as a control of equal loading of protein.
∗∗p < 0.01; ∗∗∗p < 0.001.
Based on a strategy previously introduced by Qyang et al. (2007), we used a Wnt3a-containing cell culture medium (Wnt3a 100 ng/ml, see Experimental Procedures) to stimulate the canonical Wnt/β-catenin pathway. When cells of the adherent cell fraction of human fetal hearts were expanded on plastic, they multiplied rapidly (Figure 1B) but showed a low expression of the cardiac progenitor markers ISL1, KDR, and NKX2.5, as well as the pluripotency marker OCT4 (Figure 1C).In order to improve the culturing conditions, the adherent cells were cultured on dishes pre-coated with the Engelbreth-Holm Swarm mousetumor-derived extracellular matrix extract, Geltrex (GibcoBRL). This extract, which contains basement membrane proteins such as LN-111, has been widely used for culturing stem cells and other cell types (Xu et al., 2001, Ludwig et al., 2006). When the adherent cells were cultured on Geltrex in combination with Wnt3a-containing medium, the cells divided exponentially and were passaged every other day. At 2 weeks, the adherent cells had expanded more than 1,000-fold (Figure 1B) and demonstrated activation of transcription factors involved in defining cardiac progenitors and multipotent stem cells (Figure 1C). Although cells expanded on Geltrex, in combination with the presence of Wnt3a, demonstrated increased gene-expression levels of the pluripotency marker OCT4 in comparison with the other culturing conditions, this expression was 103 times lower than that found in pluripotent human embryonic stem cells (Figure S1).As expected for activation of the canonical Wnt/β-catenin pathway, when using Wnt3a-containing medium in combination with Geltrex, the cultured cells showed an increased phosphorylation of S1490-Lrp6 and Dvl3 as well as increased levels of active (dephosphorylated) β-catenin compared with the cells of the initial adherent cell fraction (Figure 1D). These data suggest that both the Wnt3a-containing medium and Geltrex may provide important signals for expansion of cells from the adherent cell fraction of fetal human hearts, with transcriptional signatures akin to those of cardiac progenitors (Moretti et al., 2006).Exclusion of either Wnt3a or Geltrex from the culture protocol negatively affected proliferation of the cells in the initial fraction (Figure 1B) and thereby preserved survival of the limited numbers of remaining endothelial cells and cardiomyocytes among the adherent cells. This was also reflected in a relatively high mRNA expression of troponin T (TNNT2) under these culture conditions (Figure 1C).The cells were analyzed by flow cytometry using an MSC antibody panel to confirm that the adherent cells expanded for 2 weeks on Geltrex in Wnt3a-containing medium were derived from the fetal cardiac MSCs (Pittenger and Martin, 2004). With a purity of >85%, the cultured adherent cells expressed MSC markers CD105, CD90, CD73, and HLA-1, while being negative for HLA-DR and the hematopoietic lineage markers CD14, CD11, CD80, CD83, CD34, CD45, and endothelial marker CD31 (Figure S2). The cultured cells were also able to differentiate in vitro into the three mesenchymal lineages, osteoblasts, chondrocytes, and adipocytes (Figure 2), and thus fulfilled the International Society of Cellular Therapy criteria for being MSCs (Horwitz et al., 2005). Cryopreservation had no influence on the expression of the above-mentioned surface markers or the ability to differentiate into the three mesenchymal lineages.
Figure 2
Differentiation into Mesenchymal Lineages
To confirm the mesenchymal origin of the fetal cardiac MSCs they were differentiated into the three mesenchymal lineages: bone (alkaline phosphatase, ALP), cartilage (Aggrecan), and adipose tissue (oil red O, ORO). See also Figure S2. Scale bars represent 100 μm.
Characterization of Cultured Cardiac MSCs
The gene-expression profile of the cardiac MSCs was analyzed by microarray over time of culture, and we focused on the core group of transcription factors known to be important in regulation of cardiogenesis and especially the SHF development in mice (Black, 2007). The gene-expression profile of the human fetal cardiac MSCs showed only minor fluctuations over time in culture (from day 15 to day 48), including the expression of mesodermal markers TBX6, TBX1/Brachyury, and TBX18, together with the key transcription factors involved in the transcriptional network of the SHF (ISL1, GATA4, NKX2.5, FOXH1, FGF8), the FHF (TBX5, NKX2.5), as well as other markers related to cardiovascular progenitors like PDGFR-α and the stemness markers KDR, SSEA-1, and KIT (Figure 3A). The activated ISL1-GATA4 pathway in the cultured cardiac MSCs correlated well with the mRNA levels of cardiogenic bone morphogenic proteins (Cohen et al., 2007, Marvin et al., 2001) and the concomitant expression of the early cardiomyocyte markers NKX2.5 and mesoderm posterior 1 (MESP1). However, the cultured cardiac MSCs also express mature cardiomyocyte markers such as myosin heavy chain (MYH) 6 and 7, the endothelial marker VCAM1, as well as the smooth muscle markers MYH11 and myocardin (MYOCD).
Figure 3
Characterization of Cultured Cardiac MSCs
(A) The gene-expression profile of key transcription factors related to mesodermal progenitors as well as markers of cardiovascular differentiation and pluripotency was analyzed with microarray in cultured cardiac MSCs at day 15, 27, and 48. Log2 transformation of signals is depicted as bar graphs.
(B) Immunofluorescence staining (green) of ISL1, TBX18 (arrows), and NKX2.5 after 3 weeks in culture.
(C) Flow cytometry analysis of cardiac MSCs from different human fetal hearts (gestational weeks 8 and 9, n = 6) gave a quantitative assessment of the proportions of cells expressing KDR, c-KIT, and SSEA-1 (mean ± SD).
(D) Immunocytochemical staining of SSEA-1 (green) and PDGFR-α (green). Nuclei are stained with DAPI. In (B) and (D), scale bars represent 50 μm.
Another important finding is that after 3 weeks in culture (eight passages), the majority of the cardiac MSCs stained positive for ISL1 (>90%) and also for NKX2.5 (>80%) (Figure 3B). Cardiac MSCs staining positive for the mesodermal progenitor marker TBX18 were also sparsely identified (Figure 3B).Flow cytometry (Figure 3D) and immunofluorescence (Figure 3C) analyses of the cultured cardiac MSCs derived from 8- to 9-week human fetal hearts identified subpopulations of cells that express the cell stemness markers KDR, c-KIT, or SSEA-1, with low variability between cultures. Moreover, immunofluorescence staining showed that the majority of the cardiac MSCs expressed PDGFR-α.Accordingly, the gene-expression profiles in combination with the immunohistochemical and flow cytometry analyses demonstrate that the culture protocol utilized in this study reproducibly allows for large-scale expansion of fetal cardiac MSCs while retaining cardiovascular progenitor phenotypes, with low gene-expression variability during the course of culture.
Development of a Chemically Defined LN-Based Cell Culture System
We have demonstrated that a combination of a basement membrane (LN)-containing culture matrix (Geltrex) and molecules that stimulate the canonical Wnt/β-catenin signaling pathway enables propagation of cardiac MSCs with cardiovascular progenitor characteristics. To obtain a more defined matrix while maintaining successful propagation of cardiac MSCs, we explored the possibility of utilizing chemically defined LN-based matrices for expansion and differentiation of these cells. Cultured pluripotent stem cells and pluripotent cells of the inner cell mass of the blastocyst express LN-511 and LN-521 (Rodin et al., 2010, Domogatskaya et al., 2012). Since these LNs have previously been demonstrated to support clonal expansion of cultured embryonic stem cells (Rodin et al., 2014) and the LN subunits α5 and γ1 are also abundantly expressed in human fetal hearts (Figure 4A), this suggests that LN-511 and LN-521 may be suitable for derivation and expansion of cardiac MSCs. LN-211, on the other hand, might be linked to cardiomyocyte development and/or function, as it has been shown to be defective in congenital muscular dystrophicpatients with cardiomyopathy (Finsterer et al., 2010), and α2 chains were also expressed in the fetal heart (Figure 4A).
Figure 4
LN-Based Propagation and Differentiation of Cardiac MSCs
(A) Immunohistochemical staining of laminin chains α2, α5, and γ1 (all red) in a human fetal heart (gestational week 9). Nuclei are stained with DAPI. Scale bars represent 200 μm.
(B) Normalized mRNA levels ISL1 and TNNT2 from fetal cardiac MSCs cultured for 2 weeks on Geltrex, LN-511 or LN-521 in medium containing Wnt3a.
(C) Normalized mRNA levels of ISL1, KDR, NKX2.5, and TNNT2 from cardiac MSCs expanded for 2 weeks on LN-521 followed by culture on LN-211 and Geltrex for 2 weeks in medium devoid of Wnt3a. Data presented as mean ± SD of three independent experiments performed in quadruplicate. ∗∗p < 0.001.
(D) Normalized levels of TNNT2 expression in cells cultured on Geltrex (control) or LN-211 with or without blocking antibodies against α-DG and β1-integrins or corresponding isotype control antibodies. Data are presented as means ± SD of three independent experiments performed in duplicate. ∗p = 0.05.
The human fetal cardiac MSCs were cultured on human recombinant LN-511and LN-521 using the same Wnt-containing medium as described above. MSCs cultured on LN-511 and LN-521 displayed a tendency toward increased mRNA levels of ISL1 in comparison with cells cultured on Geltrex. At the same time, TNNT2 levels remained low (Figure 4B) and the expansion potential of the cells was unaffected. In order to explore the capacity of LN-211 to support cardiomyocyte differentiation, cardiac MSCs derived and expanded on LN-521 were cultured on LN-211 in a medium devoid of Wnt3a. After 2 weeks, the gene expression of TNNT2 had increased 150 times, concomitantly with a significant downregulation of KDR (Figure 4C). This indicates that LN-211 has the potential to stimulate cardiac commitment of cardiac MSCs at the gene-expression level. In order to study the signaling pathways involved, we blocked cell-laminin interactions with antibodies against α-dystroglycan (α-DG) and β1-integrin, which are important laminin receptors (Domogatskaya et al., 2012). This caused a substantial reduction of TNNT2 expression (Figure 4D), which suggests that LN-211 interacts to a large extent with the cardiac MSCs through these cellular receptors.
Differentiation into Cardiomyocytes, Smooth Muscle Cells, and Endothelial Cells
After 2 weeks of culture, the fetal cardiac MSCs expressed cardiovascular progenitor markers, supporting their potential to differentiate into the different cell types of the heart.In order to initiate cardiomyocyte differentiation, we used a protocol previously developed for differentiation of pluripotent stem cells (Lian et al., 2012, Lian et al., 2013). Expanded cardiac MSCs from fetal hearts of 6, 8, and 9 weeks’ gestation were seeded on Matrigel and canonical Wnt signaling was blocked using a defined serum-free medium to induce cardiomyocyte differentiation. A portion of the cultured cardiac MSCs derived from the 9-week heart differentiated into spontaneously beating, troponin T+ (TnT+), striated cardiomyocytes (Figures 5A and 5B and Movie S1) within 3 weeks, with no residual cardiomyocytes present before initiation of differentiation (Figure 5C). The cells derived from 6- to 8-week human fetal hearts did not differentiate into TnT+ cardiomyocytes, despite similar expression of ISL1, NKX2.5, PDGFR-α, SSEA-1, KDR, and c-KIT before initiation of differentiation.
Figure 5
Cardiomyocyte Differentiation Potential of Human Fetal Cardiac MSCs
(A) Upon exposure to cardiomyocyte differentiation medium, portions of the cardiac MSCs differentiated into elongated, striated TnT+ (green) cardiomyocytes. Scale bar represents 50 μm.
(B) A zoom-in of the box in (A) demonstrating the striations in the cardiomyocytes.
(C) All cardiac MSCs stained negative for TnT prior to initiation of the differentiation protocol. Scale bar represents 50 μm.
(D) Primary cardiomyocytes isolated from a human fetal heart were used as a positive control. Nuclei are stained with DAPI (blue). Scale bar represents 50 μm.
(E) Normalized mRNA levels of TNNT2 before and after differentiation on Matrigel and LN-211.
(F) Numbers of TnT+ cells of human fetal cardiac MSCs differentiated on plastic, LN-211, and Matrigel. Numbers of positive cells are normalized against the total number of nuclei in the same well multiplied by a factor of 100,000. Data are presented as means ± SD of three independent experiments performed in triplicate. ∗p < 0.05.
As shown in Figure 4C, we observed prominently increased levels of TNNT2 in the fetal cardiac MSCs upon culture on LN-211. Thus we replaced Matrigel, which is not chemically defined and has a batch-to-batch variability, with LN-211 and used the same cardiomyocyte differentiation protocol for the MSCs as described above (Lian et al., 2012, Lian et al., 2013). The cells differentiated on LN-211 in comparison with Matrigel showed equally increased levels of TNNT2 (Figure 5E) and also similar numbers of TnT+ cells after differentiation (Figure 5F). Thus LN-211 proved to be just as effective as Matrigel for supporting cardiomyocyte differentiation of cardiac MSCs derived from the 9-week heart.Endothelial cell differentiation was induced in cardiac MSCs by using a medium containing vascular endothelial growth factor (VEGF). The substrates used were gelatin or LNs present in the basal membranes of blood vessels (LN-521 and LN-411) (Hallmann et al., 2005, Simon-Assmann et al., 2011, Stenzel et al., 2011, Domogatskaya et al., 2012). After 3 weeks in culture, a small proportion of the cardiac MSCs expressed the endothelial marker CD31 (Figure 6, left panel) regardless of the substrate used, showing that the chemically defined laminin combination LN-521/LN-411 can support differentiation toward endothelial cells (Figure 6, left panel).
Figure 6
Differentiation into Endothelial and Smooth Muscle Cells
The cardiac MSCs underwent differentiation into endothelial cells (left panel) expressing CD31 (red) and smooth muscle cells (right panel) expressing α-SMA (green). There was no CD31 expression before differentiation, whereas the majority of the cardiac MSCs expressed α-SMA in abundance before initiation of differentiation. The intensity of the α-SMA staining did not increase as a result of differentiation but rather appeared in a more polarized fashion similar to what can be found in contractile, adult vascular smooth muscle cells exposed to PDGF-BB and TGF-β1. Human aortic endothelial cells (HAEC) and smooth muscle cells from a human carotid artery (HCtSMC) were positive controls for endothelial cells and smooth muscle cells, respectively. Nuclei are stained blue with DAPI. Scale bars represent 50 μm.
The fetal cardiac MSCs expressed α-SMA prior to differentiation (Figure 6, right panel), which has already been described for other PDGFR-α+ cells (Chong et al., 2013). After smooth muscle cell differentiation of the cardiac MSCs, the α-SMA staining intensity did not seem to increase but rather polarized into podosome-like structures (Figure 6, right panel), which can be found in vascular smooth muscle cells upon stimulation with exogenous PDGF-BB and TGF-β (Murphy and Courtneidge, 2011). Our results demonstrate that human fetal cardiac MSCs are multipotent, where different LN compositions can support their lineage specification.
Discussion
Herein, we describe that human fetal cardiac MSCs with cardiac progenitor characteristics can be propagated by using a combination of a supplemented culture medium, which stimulates the canonical Wnt/β-catenin pathway and specific laminin isoforms as cell culture substrata, without using any genetic manipulation or feeder cells. During culture, the fetal cardiac MSCs stably expressed early cardiovascular markers, and expanded rapidly without changing their phenotype during the culturing process. Excluding either Wnt3a or LN-based matrix from the culture protocol affected either cell growth or the gene expression of cardiac progenitor markers.The origin of the different subpopulations of cardiac MSCs has not been examined in this study. It has previously been reported that interstitial cells of both the atria and ventricles, display a strong expression of PDGFR-α (Chong et al., 2011, Chong et al., 2013). Chong et al. (2013) showed that PDGFR-α+ cells isolated from human fetal hearts of the second trimester were multipotent and could be differentiated into smooth muscle as well as endothelial cells, but they did not differentiate into cardiomyocytes. In the present study, the majority of the cultured cardiac MSCs stained positive for PDGFR-α. Whether these cells possibly originate from interstitial cells of the atria and ventricles remains to be elucidated, but they displayed a similar capacity to differentiate into endothelial cells and also cells with polarized α-SMA expression akin to that of mature smooth muscle cells. In contrast to the PDGFR-α+ cells previously derived from second trimester hearts (Chong et al., 2013), the fetal cardiac MSCs derived from a 9-week human heart in the present study could be differentiated into spontaneously beating, striated TnT+ cardiomyocytes, although it was only a small proportion of the cardiac MSCs that demonstrated this ability. This restricted differentiation capacity might be related to the age of the fetal heart from which the cardiac MSCs are derived, although in the present study it could not be linked to age-related differences in expression of markers known to characterize cardiovascular progenitors like KDR, NKX2.5, c-KIT, and SSEA-1 (Urbanek et al., 2003, Beltrami et al., 2003, Bearzi et al., 2007, Bruneau, 2002, Kwon et al., 2008, Durocher et al., 1996, Jho et al., 2002, Millauer et al., 1993, Motoike et al., 2003).c-KIT is a tyrosine kinase receptor that is expressed on purported cardiovascular progenitors in the heart (Urbanek et al., 2003, Beltrami et al., 2003, Bearzi et al., 2007, Bearzi et al., 2009). The origin of these cells is still unknown. Chong et al. (2013) have reported that a limited number of PDGFR-α+ cells in the atria and ventricles of the fetal hearts also express c-KIT, which is similar to our cardiac MSCs, where approximately 2% expressed c-KIT. Although subpopulations of the cardiac MSCs expressed c-KIT, we do not know if these cells are similar to the previously described cardiac progenitors in the adult heart (Urbanek et al., 2003, Beltrami et al., 2003, Bearzi et al., 2007, Bearzi et al., 2009).A small population of the fetal cardiac MSCs also expresses SSEA-1, which has been reported to represent an early marker of cardiovascular progenitors derived from pluripotent stem cells (Blin et al., 2010). The existence of a corresponding progenitor in the human fetal heart has yet to be identified, and it remains to be further investigated whether the SSEA-1-expressing cells identified within the cardiac MSC population specifically have the potential to develop into the different cell types of the heart.Some of the cultured cardiac MSCs also stained positive for the mesodermal progenitor marker TBX18 (Mommersteeg et al., 2010, Christoffels et al., 2006); future studies need to be performed in order to address whether some of the PDGFR-α+ and TBX18+ cells potentially share a developmental origin.Interestingly, the use of specific LN molecules supported lineage conversion of the cultured cardiac MSCs into cardiomyocytes and endothelial cells. By using LN-211 alone, the main component of the basement membrane surrounding adult cardiac and skeletal muscle fibers in situ (Domogatskaya et al., 2012), the cardiac MSCs could be differentiated into the cardiomyocyte lineage, with a 150 times increase of TNNT2 expression and a concomitant upregulation of NKX2.5. In addition, culture on LN-521/411, which are present in the basal membranes of vessels (Hallmann et al., 2005, Simon-Assmann et al., 2011, Stenzel et al., 2011, Domogatskaya et al., 2012), supported differentiation toward endothelial cells expressing CD31.In conclusion, we have developed a protocol for isolation and large-scale expansion of human fetal cardiac MSCs that exhibit properties of cardiac progenitor cells. These cells can be used as a tool to investigate the regenerative capacities of human fetal cardiac MSCs in a variety of contexts related to chronic and acute myocardial injury, such as hypoxia, fibrosis, and inflammation.
Experimental Procedures
Derivation and Expansion of Human Fetal Cardiac MSCs
The fetal hearts were obtained from legal terminations of pregnancy after the donor's informed consent and ethics approval from the Regional Ethics Board in Stockholm.The fetal hearts were pre-digested overnight at 4°C in a 0.5 mg/ml Trypsin solution in Hank's balanced salt solution (HBSS). The MSC fraction was prepared according to a modified version of the protocol developed by Laugwitz et al. (2005). The pre-digested heart was treated for 15 min with collagenase type II (Worthington Biochemical) 160 U/ml in HBSS, at 37°C under gentle stirring. The supernatant was centrifuged at 220 × g for 8 min and the pellet resuspended in low-glucoseDMEM supplemented with 10% fetal bovine serum (FBS) (PAA Laboratories), Mycozap (Lonza, Switzerland) and GlutaMAX (Invitrogen). The collagenase digestion was repeated until the tissue was completely dissociated. The pooled cells were washed twice and resuspended in the same medium as above. The cells were subsequently seeded on plastic and cultured for 96 hr in order to recover the adherent fraction and thereafter cryopreserved for later use. In order to propagate cardiac MSCs, the adherent stromal cell fraction was seeded at a density of 30,000 cells/cm2 on cell culture plastic coated with a thin layer of Geltrex (GibcoBRL) in DMEM/F12 supplemented with B27 (GibcoBRL), 2% FBS (PAA), MycoZap (Lonza), epidermal growth factor (10 ng/ml) (R&D Systems) and 100 ng/ml recombinant humanWnt3a (R&D Systems). The cells were passaged every 2 days, and at each passage, cells were harvested for immunocytochemical analyses as described below.In order to validate the cell culture protocol, different culturing conditions were tested, where either Geltrex or Wnt3a was excluded (gestational weeks 6.5–8, n = 3). After each passage, cells were saved for further analyses and at the end of the experiment, at 2 and 3 weeks, the cells were harvested for immunocytochemistry, PCR, and also microarray analyses.
Staining of Laminin Chains in Human Fetal Hearts
Human fetal hearts (gestational weeks 6–10, n = 3) were embedded in OCT, snap-frozen and thereafter cryo-sectioned and stained for anti-laminin α2 (MAB1922, clone 5H2, Millipore), anti-laminin α5 (MAB1924, clone 4C7, Millipore), or anti-laminin γ1 (MAB1920, clone 2 × 108, Millipore) and visualized by a secondary Alexa Fluor 568goat anti-mouse antibody (A11031, Thermo Fischer Scientific). The cell nuclei were counterstained with DAPI.
Laminin-Based Derivation and Expansion of Human Fetal Cardiac MSCs
To generate chemically defined matrices for derivation and expansion of human fetal cardiac MSCs (gestational weeks 6.5–8, n = 3), the cells were grown in wells coated with LN-511, 521, or 211, using the same culture medium as described above. The human recombinant laminins were generated as previously described (Kortesmaa et al., 2000, Doi et al., 2002, Rodin et al., 2014) or purchased from BioLamina AB (batches 80,051, 80,050, and 80,042, respectively).
Differentiation of Cardiac MSCs
For cardiomyocyte differentiation in vitro we used a modified protocol developed for human pluripotent stem cells (Lian et al., 2012, Lian et al., 2013), where the cardiac MSCs were cultured on Matrigel, LN-211 or plastic. Cardiac MSCs derived from fetal hearts of different ages (gestational week 6, 8, and 9, n = 3) were used. After 3 weeks, cells were fixed in 4% phosphate-buffered formalin and stained with a mouse monoclonal antibody against humantroponin T (TnT) (ab8295, clone 1C11, Abcam) and visualized with an Alexa Fluor 488-conjugated rabbit anti-mouse secondary antibody (A11059, Thermo Fisher Scientific). RNA extraction and qRT-PCR for TNNT2 and GAPDH were performed as described in Supplemental Experimental Procedures. For imaging of calcium signaling dynamics, cells were labeled with the Ca2+-sensitive fluorescence indicator Fluo-4/AM (10 μM; Molecular Probes, Thermo Fischer Scientific) according to the manufacturers' protocol.For differentiation toward vascular smooth muscle cells, the cardiac MSCs were seeded on gelatin-coated plastic, and cultured for 18 days in a defined medium supplemented with PDGF-BB (10 ng/ml) and TGF-β1 (2 ng/ml) (PeproTech), according to a modified protocol previously described by Cheung et al. (2014). Cells were passaged 1:4 once per week into new gelatin-coated wells. Subsequently, the cells were fixed and stained with a mouse anti-human α-smooth muscle actin primary antibody (A2547, clone 1A4; Sigma-Aldrich) and visualized by a rabbit anti-mouseAlexa Fluor 488-conjugated secondary antibody (Thermo Fischer Scientific). The experiment was performed in duplicate using cells from four different hearts of gestational age 8 and 9 weeks.For endothelial differentiation, cardiac MSCs were seeded in culture wells pre-coated overnight with a 1:4 mixture of LN-521/411 (5 μg/cm2) or gelatin (0.1%) and cultured for 21 days in EGM-2 medium (Lonza) with VEGF (50 ng/ml) from R&D Systems (Liu et al., 2007). Subsequently, the cells were fixed and stained with a monoclonal mouse anti-humanCD31 antibody (M0823, clone JC70A). Stained cells were visualized using an Alexa Fluor 568-conjugated goat anti-mouse secondary antibody (Thermo Fischer Scientific). The experiment was performed in duplicate using cells from five different hearts of gestational age 8 and 9 weeks.
Statistics
Real-time qRT-PCR data are presented as means ± SD. Student's t test (two-tailed, two samples, unequal variances) was used for statistical analysis. For analysis of TnT+ cells after differentiation, the Kruskal-Wallis test with Bonferroni correction was used. p < 0.05 was considered to indicate statistical significance.Full details on the methods used are presented in the Supplemental Experimental Procedures.
Author Contributions
K.H.G. conceived and designed the experiments together with A.M.B., S.R., I.B., O.E.S., C.Ö., C.S., M.L., and E.W., I.B., M.L., E.W., S.R., C.Ö., U.F., C.I., R.G., A.S., and C.G. performed the experiments and analyzed the data. C.S., E.A., K.L.B., C.I.E.S., M.W., E.S., P.U., E.A., K.T. and M.C. contributed reagents, materials and analysis tools. K.H.G. wrote the paper with O.E.S., C.Ö., S.R., A.M.B., and M.C.
Authors: Mathilda T M Mommersteeg; Jorge N Domínguez; Cornelia Wiese; Julia Norden; Corrie de Gier-de Vries; John B E Burch; Andreas Kispert; Nigel A Brown; Antoon F M Moorman; Vincent M Christoffels Journal: Cardiovasc Res Date: 2010-01-28 Impact factor: 10.787
Authors: J W Liu; S Dunoyer-Geindre; V Serre-Beinier; G Mai; J-F Lambert; R J Fish; G Pernod; L Buehler; H Bounameaux; E K O Kruithof Journal: J Thromb Haemost Date: 2007-01-09 Impact factor: 5.824
Authors: Chulan Kwon; Joshua Arnold; Edward C Hsiao; Makoto M Taketo; Bruce R Conklin; Deepak Srivastava Journal: Proc Natl Acad Sci U S A Date: 2007-06-18 Impact factor: 11.205
Authors: Ethan David Cohen; Zhishan Wang; John J Lepore; Min Min Lu; Makoto M Taketo; Douglas J Epstein; Edward E Morrisey Journal: J Clin Invest Date: 2007-07 Impact factor: 14.808
Authors: Sergey Rodin; Anna Domogatskaya; Susanne Ström; Emil M Hansson; Kenneth R Chien; José Inzunza; Outi Hovatta; Karl Tryggvason Journal: Nat Biotechnol Date: 2010-05-30 Impact factor: 54.908
Authors: Rami Genead; Christian Danielsson; Eva Wärdell; Anders Kjaeldgaard; Magnus Westgren; Erik Sundström; Anders Franco-Cereceda; Christer Sylvén; Karl-Henrik Grinnemo Journal: Stem Cell Res Date: 2009-11-06 Impact factor: 2.020
Authors: Jason S L Yu; Giorgia Palano; Cindy Lim; Aldo Moggio; Lauren Drowley; Alleyn T Plowright; Mohammad Bohlooly-Y; Barry S Rosen; Emil M Hansson; Qing-Dong Wang; Kosuke Yusa Journal: Stem Cells Date: 2019-04-23 Impact factor: 6.277
Authors: Karl-Henrik Grinnemo; Marie Löfling; Lubov Nathanson; Roland Baumgartner; Daniel F J Ketelhuth; Vladimir Beljanski; Lindsay C Davies; Cecilia Österholm Journal: Stem Cell Res Ther Date: 2019-12-04 Impact factor: 6.832
Authors: Kim Olesen; Noah Moruzzi; Ivana Bulatovic; Clifford Folmes; Ryounghoon Jeon; Ulrika Felldin; Andre Terzic; Oscar E Simonson; Katarina Le Blanc; Cecilia Österholm; Per-Olof Berggren; Tomas Schiffer; Sergey Rodin; Andreas Tilevik; Karl-Henrik Grinnemo Journal: Metabol Open Date: 2022-02-03
Authors: Yanhui Li; Yan Wen; Morgaine Green; Elise K Cabral; Prachi Wani; Fan Zhang; Yi Wei; Thomas M Baer; Bertha Chen Journal: Stem Cell Res Ther Date: 2017-07-04 Impact factor: 6.832
Authors: Mustafa M Tashkandi; Saqer F Alsaqer; Thabet Alhousami; Faiza Ali; Yu-Chiao Wu; Jennifer Shin; Pushkar Mehra; Larry M Wolford; Louis C Gerstenfeld; Mary B Goldring; Manish V Bais Journal: Sci Rep Date: 2020-11-19 Impact factor: 4.379